Unique Technology/Candidates
Nido is a clinical-stage neuroscience company focused on genetically validated targets in neuromuscular diseases.
SBMA is caused by an X-linked genetic mutation of the androgen receptor (AR) gene that results in the loss of skeletal muscle and motor neuron function. Nido’s lead candidate, NIDO-361, is a novel small molecule that binds to the BF3 site – a distinct site from where typical AR targeting small molecules bind – to restore healthy cell function. NIDO-361 is being studied in an ongoing phase II clinical study.
Most Recent Funding
Series B
- Bioluminescence Ventures
- 5AM Ventures
- Abingworth
- Bessemer
- Osage
- Eli Lilly
Total: USD $109M
Current Clinical Focus
The main focus is the execution of the ongoing Phase 2 study of NIDO-361
Phase 1 study completed in November 2023.
Observational study ongoing
Therapeutic Modality
Small molecules
Therapeutic Area / Disease
Neurological rare disease /SBMA (Kennedy’s disease)
Company Location
Boston, MA
